Alyftrek, vanzacaftor/tezacaftor/deutivacaftor
Named-patient access overview. Alyftrek is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Alyftrek
Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is manufactured by Vertex Pharmaceuticals and indicated for cystic fibrosis in patients aged 6 and older who have at least one F508del mutation or another responsive CFTR mutation (roughly 94 responsive mutations, ~31 additional vs. Trikafta). It is the next-generation oral once-daily CFTR triple combination, approved by the US FDA in December 2024 as successor to Trikafta. Carries a DILI boxed warning. Available to international patients through Named Patient Program or personal-import pathways via Reserve Meds.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Alyftrek
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Alyftrek for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Alyftrek is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Alyftrek in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Alyftrek
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.